AOD-9604
Available Suppliers & Pricing
Price-drop alert for AOD-9604
Get an email when the lowest listed price falls below your target. No account required.
Current lowest listed price: $25.00
By setting an alert, you request catalog price-alert emails for this research-use-only product. Alerts are informational, not medical guidance. You can unsubscribe from any alert email.
Price history
Review recorded in-stock supplier catalog prices for AOD-9604.
Summary
AOD-9604 is a synthetic peptide fragment consisting of amino acids 176-191 from the C-terminus of human growth hormone (hGH) with a tyrosine residue added at the N-terminus. Developed by Metabolic Pharmaceuticals Limited, it was designed to mimic hGH's lipolytic (fat-burning) properties without stimulating IGF-1 production or causing insulin resistance. The peptide operates by activating beta-3 adrenergic receptors in adipose tissue, promoting lipolysis while inhibiting lipogenesis. Initial 12-week clinical trials showed modest weight loss (average 2.6 kg vs 0.8 kg placebo), but a larger 24-week trial of 536 subjects failed to demonstrate significant efficacy, leading to termination of development in 2007. Despite lack of FDA approval, AOD-9604 remains available through compounding pharmacies and gray market sources. It is prohibited by WADA as a non-approved substance under category S.0. The peptide has shown potential applications beyond obesity, including cartilage repair in osteoarthritis models.
Potential Benefits
Weight Loss and Fat Metabolism
- Lipolytic Activity: Stimulates breakdown of stored fat through activation of beta-3 adrenergic receptors in adipose tissue, increasing fat oxidation and plasma glycerol levels [1][2]
- Lipogenesis Inhibition: Prevents transformation of non-fat food materials into body fat, potentially reducing new fat accumulation [3][4]
- Selective Action: Targets fat metabolism without competing for hGH receptors or inducing cell proliferation, avoiding muscle-building effects of full-spectrum growth hormone [2]
- Weight Reduction: In 12-week clinical trials, subjects receiving 1 mg/day lost an average of 2.6 kg compared to 0.8 kg in placebo group [5][6]
Metabolic Safety Profile
- No IGF-1 Elevation: Unlike intact hGH, AOD-9604 produces no effect on serum IGF-1 levels, eliminating growth-related side effects [7]
- Preserved Insulin Sensitivity: Chronic treatment showed no adverse effects on insulin sensitivity or carbohydrate metabolism, distinguishing it from full hGH therapy [1][7]
- Glucose Metabolism: Oral glucose tolerance testing revealed no negative impact on glycemic control [7]
Additional Therapeutic Potential
- Cartilage Repair: Intra-articular injections enhanced cartilage regeneration in rabbit osteoarthritis models, with combined AOD-9604 and hyaluronic acid showing superior efficacy over either treatment alone [8]
- Joint Recovery: May provide anti-inflammatory effects and support joint health beyond fat reduction applications [8]
Safety Information
Clinical Safety Profile
- Excellent Tolerability: Across six randomized, double-blind, placebo-controlled trials totaling approximately 900 participants, AOD-9604 displayed safety profile indistinguishable from placebo with no treatment-related withdrawals or serious adverse events [7]
- Minimal Side Effects: Most commonly reported effects include mild injection site irritation, transient fatigue, and headache [9]
- No Antibody Formation: No anti-AOD-9604 antibodies detected in any clinical trial participants, indicating low immunogenicity risk [7]
- Rapid Metabolism: Pharmacokinetic studies show 3-minute half-life following IV administration and approximately 40% oral bioavailability, reducing accumulation concerns [10]
Regulatory and Legal Status
- FDA Status: NOT approved by FDA or any government health authority for medical use; remains an investigational compound [5]
- WADA Prohibition: Classified as prohibited substance under category S.0 (non-approved substances) and S2 (growth hormone fragments); banned at all times in competitive sports
- Clinical Development Terminated: Development discontinued in 2007 after 24-week trial of 536 subjects failed to demonstrate significant weight loss efficacy [5][6]
Gray Market Concerns
- Unregulated Sources: Available through internet "black market" and unregulated suppliers without prescription, raising quality and safety concerns
- Contamination Risk: Products from unregulated sources may contain heavy metals or impurities; quality cannot be guaranteed
- Compounding Pharmacy Access: Available through some licensed compounding pharmacies with prescription, though regulatory oversight varies by jurisdiction
- Long-term Safety Unknown: Limited research on extended-use effects; comprehensive long-term risk profile remains unclear [9]